Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases

QR Code

Effect of dapagliflozin in patients with heart failure on reducing cardiovascular mortality in federal project on the prevention of cardiovascular diseases

Aim. To assess the effect of dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF) on reducing cardiovascular mortality as the main goal of a federal project on the prevention of cardiovascular diseases.Material and methods. All adult Russian patients with a documented...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. V. Zhuravleva, S. N. Tereshchenko, I. V. Zhirov, S. V. Villevalde, T. V. Marin, Yu. V. Gagarina
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-11-01
Series:	Российский кардиологический журнал
Subjects:	dapagliflozin heart failure targets cardiovascular mortality federal project on the prevention of cardiovascular diseases
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/4142
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Сost-effectiveness of preventing cardiovascular death and achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using valsartan+sacubitril, dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2023-04-01)

Cost-effectiveness of dapagliflozin as part of various treatment regimens for prevention of cardiovascular death and achieving the target indicator "Reduction of cardiovascular mortality" of the State Program "HealthCare Development" in patients with heart failure with reduced ejection fraction
by: M. V. Zhuravleva, et al.
Published: (2024-08-01)

Cost-effectiveness of using sodium-glucose cotransporter type 2 inhibitors as a part of therapy for cardiovascular death prevention and achieving the Reduction of Cardiovascular Mortality indicator of the Healthcare Development state program in patients with chronic kidney disease and resistant hypertension
by: M. V. Zhuravleva, et al.
Published: (2025-05-01)

Cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and reducing cardiovascular mortality within the State Program "Health Development" in patients with heart failure
by: M. V. Zhuravleva, et al.
Published: (2023-12-01)

Effect of ticagrelor in patients with acute coronary syndrome on the achievement of the targets of federal project on the prevention of cardiovascular diseases: 3-year perspective estimates
by: M. V. Zhuravleva, et al.
Published: (2020-12-01)

Effects of ticagrelor in patients with acute coronary syndrome on the targets of the national cardiovascular program
by: M. V. Zhuravleva, et al.
Published: (2020-06-01)

Patients with Combination of Cardiovascular Diseases and Type 2 Diabetes in RECVASA and REGION Registries: Multimorbidity, Outcomes and Potential Effect of Dapagliflozin in the Russian Clinical Practice
by: M. M. Loukianov, et al.
Published: (2020-03-01)

Cardiovascular mortality rate in Moscow and St. Petersburg in 2015 and 2018
by: S. A. Boytsov, et al.
Published: (2021-02-01)

The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases"
by: M. V. Zhuravleva, et al.
Published: (2022-03-01)

Basic Aspects of Seasonal Cardiovascular Mortality
by: G. F. Andreeva, et al.
Published: (2021-03-01)

Evaluation of the effect of the use of the drug ticagrelor in patients with acute coronary syndrome on achieving the target indicator “reduction of mortality from diseases of the circulatory system” in 2022-2024
by: M. V. Zhuravleva, et al.
Published: (2022-01-01)

Contribution of ticagrelor therapy in patients with acute coronary syndrome and patients with myocardial infarction to the achievement of State Program "Health Development" target in Russia as a whole and Russian regions in 2023-2025
by: M. V. Zhuravleva, et al.
Published: (2024-02-01)

Current status of the problem of cardiovascular diseases in the Nizhny Novgorod region: possible ways to reduce mortality
by: N. Yu. Borovkova, et al.
Published: (2022-06-01)

Comparative Analysis of All-cause and Cardiovascular Mortality in Moscow and Irkutsk
by: F. I. Belyalov, et al.
Published: (2016-09-01)

The role of clinical guidelines in reducing the burden of cardiovascular diseases.
by: R. V. Polibin, et al.
Published: (2025-06-01)

Central directions for reducing cardiovascular mortality: what can be changed today?
by: E. V. Shlyakhto, et al.
Published: (2020-08-01)

WHY CARDIOVASCULAR MORTALITY IN MOSCOW IS LOWER THAN IN OTHER REGIONS OF THE RUSSIAN FEDERATION?
by: N. V. Pogosova, et al.
Published: (2015-04-01)

Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
by: S. N. Tereshchenko, et al.
Published: (2020-06-01)

Cardiovascular risk management system: prerequisites for developing, organization principles, target groups
by: E. V. Shlyakhto, et al.
Published: (2019-11-01)

Cardiovascular risk in type 2 diabetes patients
by: O. D. Ostroumova, et al.
Published: (2018-08-01)

Factors influencing cardiovascular mortality in Russian population
by: S. A. Shalnova, et al.
Published: (2005-02-01)

Main directions of prophylaxis of untimely mortality from cardiovascular diseases
by: A. T. Adamyan, et al.
Published: (2009-04-01)

MORTALITY AND LOST YEARS OF LIFE AS A RESULT OF CARDIOVASCULAR PREMATURE DEATHS
by: S. A. Boitsov, et al.
Published: (2014-04-01)

Association between cardiovascular mortality and deprivation in the adult population of Russia
by: A. A. Zelenina, et al.
Published: (2024-04-01)

THE COMPARISON OF REGIONAL MORTALITY FROM CARDIOVASCULAR DISEASES IN THE YEARS 2006-2014 BY NOSOLOGICAL AND AGE-RELATED REGARDS
by: A. S. Galyavich, et al.
Published: (2016-12-01)

CARDIOVASCULAR MORTALITY IN 12 RUSSIAN FEDERATION REGIONS – PARTICIPANTS OF THE “CARDIOVASCULAR DISEASE EPIDEMIOLOGY IN RUSSIAN REGIONS” STUDY
by: S. A. Shalnova, et al.
Published: (2012-10-01)

SMOKING AND CARDIOVASCULAR MORTALITY IN TOMSK INHABITANTS AS A TYPICAL CITY OF WESTERN SIBERIA
by: E. V. Efimova, et al.
Published: (2017-12-01)

Expert opinion on the article "Association between cardiovascular mortality and deprivation in the adult population of Russia"
by: V. I. Perkhov
Published: (2024-04-01)

Impact of non-high-density lipoprotein cholesterol in mortality and cardiovascular events among middle-aged Russian men: 40 years ago and now
by: S. A. Shalnova, et al.
Published: (2024-12-01)

REGIONAL SPECIFICS OF CARDIOVASCULAR MORBIDITY AND MORTALITY
by: M. G. Moskvicheva, et al.
Published: (2016-08-01)

MORBIDITY AND MORTALITY FROM CARDIOVASCULAR DISEASES ACCORDING TO THE SEA-LEVEL RELATED ALTITUDE OF A REGION
by: A. A. Dotdaeva, et al.
Published: (2014-12-01)

NOSOLOGICALLY AND AGE-STRATIFIED MORTALITY STRUCTURE FROM CARDIOVASCULAR DISEASES IN THE YEARS 2006 AND 2014
by: I. V. Samorodskaya, et al.
Published: (2016-06-01)

BODY WEIGHT AND ITS IMPACT ON ALL-CAUSE AND CARDIOVASCULAR MORTALITY IN RUSSIA
by: S. A. Shalnova, et al.
Published: (2014-02-01)

Biomarkers in predicting mortality from cardiovascular events in patients with heart failure and an implanted cardioverter-defibrillator
by: N. N. Ilov, et al.
Published: (2023-10-01)

Sex-Specific Cardiovascular Risks and Mortality in Patients with Panhypopituitarism: A Nationwide Cohort Study
by: Seung Shin Park, et al.
Published: (2025-06-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

The beneficial effects of dapagliflozin on the course of experimental urate nephrolithiasis
by: V. Yu. Perfil’ev, et al.
Published: (2017-04-01)

Response to an expert opinion on the article "Association between cardiovascular mortality and deprivation in the adult population of Russia"
by: A. A. Zelenina, et al.
Published: (2024-09-01)

Prediabetes: prevalence, associations with cardiovascular risk factors and contribution to survival in the Russian population
by: Yu. A. Balanova, et al.
Published: (2024-06-01)